{"disease":{"id":"arthritis-rheumatoid","name":"arthritis rheumatoid"},"drugs":{"marketed":[{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe non-radiographic axial spondyloarthritis and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and rheumatoid arthritis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and Crohn's disease and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":11,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01685424","title":"Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)","phase":"","overall_status":"COMPLETED","enrollment_count":79189,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT03456206","title":"Chronic Inflammatory Disease, Lifestyle and Risk of Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":57053,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT00346216","title":"Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":24081,"lead_sponsor_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","has_results":true},{"nct_id":"NCT05603728","title":"Exactech Shoulder Post Market Clinical Follow-up Study","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Exactech","has_results":false},{"nct_id":"NCT07484243","title":"Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Yuanyuan Zhang","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT04721821","title":"Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.","phase":"","overall_status":"COMPLETED","enrollment_count":7807,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03964649","title":"Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics","phase":"","overall_status":"COMPLETED","enrollment_count":7308,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04402086","title":"Rheumatology Patient Registry and Biorepository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT00413699","title":"Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":4488,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02092467","title":"Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":4372,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07363980","title":"Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":4000,"lead_sponsor_name":"Ellen Margrethe Hauge","has_results":false},{"nct_id":"NCT04821206","title":"PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Liga Panamericana de Asociaciones de Reumatologia (PANLAR)","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT04333147","title":"Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":2916,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00741793","title":"Biologic Treatment Registry Across Canada","phase":"","overall_status":"COMPLETED","enrollment_count":2821,"lead_sponsor_name":"Janssen Inc.","has_results":false},{"nct_id":"NCT05883371","title":"IMPACT - AndHealth Autoimmune Research Registry","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"AndHealth","has_results":false},{"nct_id":"NCT04384068","title":"The Safety and Effectiveness of Tocilizumab in Rheumatoid Arthritis","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03662919","title":"One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":2274,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT05796245","title":"A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis","phase":"","overall_status":"COMPLETED","enrollment_count":2207,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06246123","title":"A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants","phase":"","overall_status":"RECRUITING","enrollment_count":2040,"lead_sponsor_name":"Eisai Korea Inc.","has_results":false},{"nct_id":"NCT05572567","title":"Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":1972,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01856309","title":"Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1820,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT03970837","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1764,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04721808","title":"A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":1712,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01604343","title":"A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1670,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT03980483","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1537,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04749875","title":"Study of Leukocyte Populations in Patients With Chronic Inflammatory","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04428424","title":"Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1493,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03387423","title":"Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":1459,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT01208181","title":"A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1404,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT05855109","title":"Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors","phase":"","overall_status":"COMPLETED","enrollment_count":1304,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05647577","title":"The Relationship Between Inflammatory ARTritis and CArdiac DIseAse","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1285,"lead_sponsor_name":"University Hospital, Gentofte, Copenhagen","has_results":false},{"nct_id":"NCT02728934","title":"Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":1279,"lead_sponsor_name":"Janssen Scientific Affairs, LLC","has_results":false},{"nct_id":"NCT04267614","title":"This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.","phase":"","overall_status":"COMPLETED","enrollment_count":1226,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04089514","title":"A Real-world Study of Imraldi® Use","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT04031469","title":"A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease","phase":"","overall_status":"SUSPENDED","enrollment_count":1000,"lead_sponsor_name":"ProgenaBiome","has_results":false},{"nct_id":"NCT07000916","title":"Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Université Catholique de Louvain","has_results":false},{"nct_id":"NCT00289133","title":"Gamma Vacuum Foil (GVF) Versus Cross-linked Polyethylene in Total Knee Arthroplasty Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":938,"lead_sponsor_name":"DePuy Orthopaedics","has_results":true},{"nct_id":"NCT04247672","title":"The ATtune Knee Outcome Study","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Spaarne Gasthuis","has_results":false},{"nct_id":"NCT01606761","title":"A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":878,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT01638013","title":"A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":843,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT06965322","title":"Study on the Detection of Pleuropulmonary Manifestations in Rheumatoid Arthritis","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Medical University Innsbruck","has_results":false},{"nct_id":"NCT04255394","title":"Exceed ABT Acetabular Cup Cementless System","phase":"","overall_status":"COMPLETED","enrollment_count":677,"lead_sponsor_name":"Zimmer Biomet","has_results":true},{"nct_id":"NCT03480529","title":"Monitoring the IMmUological TOXicity of Drugs","phase":"","overall_status":"COMPLETED","enrollment_count":662,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT02137226","title":"BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":645,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT02405780","title":"A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":645,"lead_sponsor_name":"Fujifilm Kyowa Kirin Biologics Co., Ltd.","has_results":true},{"nct_id":"NCT03429426","title":"Progression of Bone Erosions in Rheumatoid Arthritis Assessed by HR-pQCT and Conventional X-ray","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":625,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT01711814","title":"A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06072287","title":"The Living With a Long-Term Condition Study","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"King's College London","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}